Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Descending) Package Effective Date Package Discontinuation Date Status
51662-1483-01 51662-1483 SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT SOLU-MEDROL(R) METHYLPREDNISOLONE SODIUM SUCCINAT 500.0 mg/4mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Dec. 14, 2019 In Use
55513-0141-01 55513-0141 trastuzumab-anns Kanjinti 150.0 mg/7.15mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct. 28, 2019 In Use
55513-0224-01 55513-0224 rituximab-arrx Riabni 100.0 mg/10mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
55513-0326-01 55513-0326 rituximab-arrx Riabni 500.0 mg/50mL Immunotherapy Monoclonal Antibody CD20 Intravenous Jan. 6, 2021 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
68001-0480-22 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68001-0480-35 68001-0480 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 14, 2020 In Use
68083-0381-01 68083-0381 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
70700-0169-22 70700-0169 Irinotecan hydrochloide Irinotecan hydrochloide 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Nov. 18, 2019 In Use
42658-0019-01 42658-0019 Daunorubicin hydrochloride Daunorubicin Hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jan. 20, 2020 In Use
43598-0389-57 43598-0389 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous April 22, 2019 In Use
43598-0865-60 43598-0865 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Nov. 1, 2019 In Use
47335-0323-40 47335-0323 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0895-40 47335-0895 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
47335-0939-40 47335-0939 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 26, 2020 In Use
49315-0007-10 49315-0007 Arsenic trioxide Arsenic trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Sept. 3, 2019 In Use
49315-0008-03 49315-0008 Doxorubicin hydrochloride DOXORUBICIN HYDROCHLORIDE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Sept. 14, 2020 In Use
54868-2522-00 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-2522-01 54868-2522 Filgrastim Neupogen 300.0 ug/mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous June 8, 1994 In Use
54868-3050-00 54868-3050 Filgrastim Neupogen 480.0 ug/.8mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous Aug. 14, 2006 In Use
54868-5020-00 54868-5020 Filgrastim Neupogen 300.0 ug/.5mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Intravenous March 11, 2004 In Use
50633-0210-11 50633-0210 Glucarpidase Voraxaze 1000.0 [USP'U]/1 Ancillary Therapy Chemoprotective Antidote Intravenous April 1, 2012 In Use
55150-0175-01 55150-0175 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous July 6, 2016 In Use
55150-0176-04 55150-0176 Granisetron Hydrochloride Granisetron Hydrochloride 4.0 mg/4mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous July 6, 2016 In Use
55648-0661-01 55648-0661 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 30, 2008 In Use
55648-0661-02 55648-0661 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 30, 2008 In Use
55648-0661-03 55648-0661 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 30, 2008 In Use
55648-0662-01 55648-0662 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 3, 2008 In Use
55648-0662-02 55648-0662 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous March 3, 2008 In Use
63323-0733-10 63323-0733 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sept. 5, 2001 In Use
63323-0733-11 63323-0733 Mesna Mesna 100.0 mg/mL Ancillary Therapy Chemoprotective Detoxifying Agent Intravenous Sept. 5, 2001 In Use
23155-0240-41 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
23155-0240-42 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
23155-0240-43 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
00338-1762-41 00338-1762 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 27, 2006 July 25, 2012 No Longer Used
00781-3011-80 00781-3011 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous July 27, 2007 Oct. 31, 2011 No Longer Used
10019-0905-01 10019-0905 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 19, 2010 Sept. 30, 2013 No Longer Used
10019-0905-02 10019-0905 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 19, 2010 Sept. 30, 2013 No Longer Used
10019-0905-03 10019-0905 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 19, 2010 Sept. 30, 2013 No Longer Used
10019-0905-17 10019-0905 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 19, 2010 Sept. 30, 2013 No Longer Used
16729-0297-83 16729-0297 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Oct. 20, 2016 In Use
16729-0298-05 16729-0298 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Oct. 20, 2016 In Use
50111-0823-76 50111-0823 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Feb. 14, 2017 Feb. 16, 2017 No Longer Used
50111-0824-78 50111-0824 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Feb. 14, 2017 Feb. 16, 2017 No Longer Used
52125-0809-52 52125-0809 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Jan. 9, 2014 April 15, 2016 No Longer Used
54868-5888-00 54868-5888 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 8, 2008 In Use
55390-0121-01 55390-0121 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 July 31, 2012 No Longer Used
55390-0121-10 55390-0121 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 July 31, 2012 No Longer Used
55390-0307-01 55390-0307 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 Feb. 28, 2011 No Longer Used
55390-0307-10 55390-0307 Ondansetron Ondansetron Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Dec. 26, 2006 Feb. 28, 2011 No Longer Used

Found 10,000 results in 9 milliseconds — Export these results